Search results for "Observational study"

showing 10 items of 776 documents

Efficacy and Renal Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus Also Receiving Metformin: A Real-Life Experience.

2017

Introduction. This study aimed at evaluating the efficacy and safety of dapagliflozin in patients with type 2 diabetes (T2D) who also received metformin in clinical practice in Italy. Methods. This was a retrospective observational study and it included data from patients who received dapagliflozin 10 mg once daily in conjunction with metformin for 12 months (DAPA + MET). In those with inadequate glycemic control, insulin or glimepiride was added after 30 days (DAPA + MET + other glucose-lowering drugs). Efficacy assessments included glycosylated hemoglobin (HbA1c) levels at 6 and 12 months, as well as body mass index (BMI) and lipid parameters at 12 months. Safety was also assessed. Result…

Blood GlucoseMalemedicine.medical_specialtyArticle Subjectendocrine system diseasesEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismType 2 diabeteslcsh:Diseases of the endocrine glands. Clinical endocrinologyBody Mass Index03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyGlucosidesInternal medicineDiabetes mellitusmedicineHumansHypoglycemic Agents030212 general & internal medicineDapagliflozinBenzhydryl CompoundsAgedRetrospective StudiesGlycated Hemoglobinlcsh:RC648-665business.industryType 2 Diabetes Mellitusnutritional and metabolic diseasesRetrospective cohort studyMiddle Agedmedicine.diseaseMetforminMetforminTreatment OutcomechemistryDiabetes Mellitus Type 2Observational studyDrug Therapy CombinationFemalebusinessBody mass indexmedicine.drugResearch ArticleJournal of diabetes research
researchProduct

Subclinical atherosclerosis and history of cardiovascular events in Italian patients with rheumatoid arthritis: Results from a cross-sectional, multi…

2017

Supplemental Digital Content is available in the text

Blood GlucoseMalerheumatoid arthritisCross-sectional studyType 2 diabetesTriglycerideArthritis Rheumatoid0302 clinical medicineRisk FactorsCardiovascular DiseasePrevalence030212 general & internal medicineMyocardial infarctionStrokeSubclinical infectionAged 80 and overMetabolic SyndromeMetabolic Syndrome XGeneral MedicineMiddle Agedinflammatory processCholesterolItalyCardiovascular DiseasesRheumatoid arthritisAtherosclerosiHypertensionComputingMethodologies_DOCUMENTANDTEXTPROCESSINGFemaleHumanResearch ArticleAdultmedicine.medical_specialtyAdolescentsubclinical atherosclerosisObservational Study03 medical and health sciencesYoung Adultcardiovascular eventsInternal medicinemedicineHumansTriglyceridesAged030203 arthritis & rheumatologyCross-Sectional Studiebusiness.industryRisk Factor6900medicine.diseaseAtherosclerosisCross-Sectional StudiesDiabetes Mellitus Type 2Physical therapyMetabolic syndromebusinessRheumatismtraditional cardiovascular risk factorMedicine
researchProduct

Prevalence of type 2 diabetes and impaired fasting glucose in patients affected by rheumatoid arthritis: Results from a cross-sectional study.

2017

Abstract Although the better management of rheumatoid arthritis (RA) has significantly improved the long-term outcome of affected patients, a significant proportion of these may develop associated comorbidities including cardiometabolic complications. However, it must be pointed out that a comprehensive cardiometabolic evaluation is still poorly integrated into the management of RA patients, due to a limited awareness of the problem, a lack of appropriate clinical studies, and optimal strategies for cardiovascular (CV) risk reduction in RA. In addition, although several studies investigated the possible association between traditional CV risk factors and RA, conflicting results are still av…

Blood GlucoseMalerheumatoid arthritisTime FactorsCross-sectional studyType 2 diabetesAdrenal Cortex HormoneBody Mass IndexArthritis Rheumatoid0302 clinical medicineimpaired fasting glucoseAdrenal Cortex HormonesRisk FactorsRheumatoidCardiovascular DiseasePrevalence030212 general & internal medicineMedicine (all)Diabetes MellituGeneral MedicineMiddle AgedC-Reactive ProteinCholesterolcardiovascular risk; impaired fasting glucose; inflammation; rheumatoid arthritis; type 2 diabetes;Cardiovascular DiseasesCohortHypertensionFemaletype 2 diabetesCase-Control Studiecardiovascular risk; impaired fasting glucose; inflammation; rheumatoid arthritis; type 2 diabetes; Adrenal Cortex Hormones; Adult; Aged; Arthritis Rheumatoid; Blood Glucose; Body Mass Index; C-Reactive Protein; Cardiovascular Diseases; Case-Control Studies; Cholesterol; Cross-Sectional Studies; Diabetes Mellitus Type 2; Female; Glucose Intolerance; Humans; Hypertension; Male; Middle Aged; Prevalence; Risk Factors; Time Factors; Medicine (all)Type 2Research ArticleArthritiHumanAdultcardiovascular riskmedicine.medical_specialtyTime FactorObservational StudyNO03 medical and health sciencesInternal medicineDiabetes mellitusGlucose Intolerancemedicinecardiovascular risk impaired fasting glucose inflammation rheumatoid arthritis type 2 diabetesHumansAged030203 arthritis & rheumatologyCross-Sectional Studietype 2 diabetebusiness.industryRisk Factor6900Case-control studyrheumatoid arthritimedicine.diseaseImpaired fasting glucoseSettore MED/16 - ReumatologiaCross-Sectional StudiesDiabetes Mellitus Type 2inflammationCase-Control StudiesMetabolic syndromebusinessBody mass index
researchProduct

Home blood pressure control is low during the critical morning hours in patients with hypertension: the SURGE observational study

2011

Background. The morning blood pressure (BP) surge is associated with a peak increase in vascular events. Objective. The aim of this observational study was to evaluate morning BP control in treated hypertensive patients using home BP (HBP) monitoring and to compare these findings with clinic BP control. Methods. Clinic BP was measured twice during a 2-week period, prior to medication. Seated HBP was measured, using a BHS-validated device, three times per day over a 2-week period. Assessments included morning (06:00–11:59), lunchtime (12:00–14:00) and evening (18:00–22:00) HBP control (all <135/85 mmHg) and clinic BP (<140/90 mmHg) control. Results. A total of 15 618 patients were assessed. …

Blood pressure controlAdultMalemedicine.medical_specialtyEveningTime FactorsAdolescentPopulationYoung AdultMedicineHumansIn patientHome blood pressure monitoring hypertension morning blood pressure control.educationAntihypertensive AgentsMorningAgedAged 80 and overeducation.field_of_studybusiness.industryBlood Pressure DeterminationMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREBlood Pressure Monitoring AmbulatoryMiddle AgedSurgeryCircadian RhythmBlood pressureTreatment OutcomeAnesthesiaHypertensionObservational studyFemaleDrug MonitoringFamily Practicebusiness
researchProduct

Determination of Brain Death/Death by Neurologic Criteria

2020

Importance: There are inconsistencies in concept, criteria, practice, and documentation of brain death/death by neurologic criteria (BD/DNC) both internationally and within countries. Objective: To formulate a consensus statement of recommendations on determination of BD/DNC based on review of the literature and expert opinion of a large multidisciplinary, international panel. Process: Relevant international professional societies were recruited to develop recommendations regarding determination of BD/DNC. Literature searches of the Cochrane, Embase, and MEDLINE databases included January 1, 1992, through April 2020 identified pertinent articles for review. Because of the lack of high-quali…

Brain Deathmedicine.medical_specialtyBiomedical ResearchNeurologyBrain Death Death by Neurologic CriteriaApneaPhysical examination01 natural scienceslaw.inventionDiagnosis Differential03 medical and health sciences0302 clinical medicinePharyngeal reflexRandomized controlled triallawmedicineHumansNervous System Physiological Phenomena030212 general & internal medicineComa0101 mathematicsIntensive care medicineComamedicine.diagnostic_testbusiness.industry010102 general mathematicsApneaGeneral MedicineObservational studyNeurosurgerymedicine.symptombusinessBrain StemJAMA
researchProduct

2 years in the life of COPD patients: Evolution of GOLD 2011 classification in the 'real-life' DACCORD study

2016

Introduction Limited data are available on the progression of COPD categorised according to GOLD 2011. We analysed data from the ongoing, non-interventional, observational DACCORD study and compared baseline GOLD 2011 categorisation with that of 1 and 2-years after inclusion. Methods Patients with a diagnosis of COPD were recruited into DACCORD following either a change or initiation of maintenance medication. Baseline exacerbations data (collected over 6 months) were annualised for GOLD categorisation at baseline; COPD symptoms were evaluated using the COPD Assessment Test (CAT) at baseline as well as the 1 year and 2 year visit. Data on exacerbations were collected every 3 months up to 2 …

COPDPediatricsmedicine.medical_specialtyCopd patientsbusiness.industryMean agemedicine.diseaseLower riskSecondary caremedicineCopd assessment testObservational studybusinessProgressive disease6.1 Epidemiology
researchProduct

Late Breaking Abstract - Validation of a tool for the assessment of disease awareness (DA) in COPD

2017

Background: DA could influence adherence to treatment and outcomes. No validated tools are available to assess DA in COPD Aims: To generate a tool able to explore DA in COPD patients, the Disease Awareness in COPD Questionnaire (DACQ) Methods: A 2-step Delphi approach was used to develop a questionnaire that was tested for validity in a cohort of COPD patients of an Italian observational, multicenter, prospective study (SAT study - NCT02689492) Results: Consensus on a 27-item provisional questionnaire was obtained with 2 Delphi rounds. Factor analysis showed a 4-factor solution accounting for 35% of variance; each factor (disease acceptance, awareness of treatment needs, disease knowledge, …

COPDmedicine.medical_specialtyRasch modelbusiness.industryDelphi methodmedicine.diseaseSpearman's rank correlation coefficientCronbach's alphaCohortmedicinePhysical therapyObservational studybusinessProspective cohort studyEpidemiology
researchProduct

Switch from LABA+ICS to a LABA/LAMA combination in symptomatic women with COPD – an analysis of the observational DACCORD study

2018

Introduction: COPD prevalence in women has increased in recent years and the importance of avoiding ICS use in this group, because of its potential negative impact on comorbidities such as osteoporosis and diabetes, has become a topic of interest. In this real-life cohort women with COPD that were switched from LABA+ICS treatment to a fixed combination of LABA/LAMA were followed for 1 year. Methods: DACCORD is a prospective, non-interventional 2-year study in the primary and secondary care setting throughout Germany. Patients were recruited after a change in, or initiation of COPD maintenance medication. Data collected at baseline and every 3 months included moderate/severe exacerbations an…

COPDmedicine.medical_specialtybiologyExacerbationbusiness.industryOsteoporosisLamamedicine.diseasebiology.organism_classificationInternal medicineDiabetes mellitusCohortmedicinePopulation studyObservational studybusinessClinical Problems
researchProduct

Dual bronchodilation vs triple therapy in the &amp;ldquo;real-life&amp;rdquo; COPD DACCORD study

2018

Roland Buhl,1 Carl-Peter Cri&amp;eacute;e,2 Peter Kardos,3 Claus F Vogelmeier,4 Konstantinos Kostikas,5 Nadine S Lossi,6 Heinrich Worth7 1Pulmonary Department, Mainz University Hospital, Mainz, 2Department of Sleep and Respiratory Medicine, Evangelical Hospital Goettingen-Weende, Bovenden, 3Group Practice and Centre for Allergy, Respiratory and Sleep Medicine, Red Cross Maingau Hospital, Frankfurt am Main, 4Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University Marburg, Member of the German Center for Lung Research (DZL), Marburg, Germany; 5WorldWide Medical Affairs Respiratory, Novartis Pharma AG, Basel, Switzerland;…

COPDmedicine.medical_specialtybusiness.industrymedicine.drug_classGeneral MedicineInternational Journal of Chronic Obstructive Pulmonary Diseasemedicine.diseaseClinical trial03 medical and health sciences0302 clinical medicinePrior Therapy030228 respiratory systemMaintenance therapyBronchodilatorInternal medicineCohortMedicineCorticosteroidObservational study030212 general & internal medicinebusinessInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study.

2021

Abstract Background and aims Central and Eastern Europe (CEE) is a largely understudied region, despite having the highest cardiovascular disease mortality in Europe. This analysis aimed to assess the proportion of patients in CEE who achieved their LDL-C goals based on individual cardiovascular risk recommended by the 2016 and 2019 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guidelines. Methods The DA VINCI study was a cross-sectional observational study of primary and secondary prevention patients receiving lipid-lowering therapy across Europe between June 2017 and November 2018. Results In total, 2154 patients were enrolled from the Czech Republic (n = 509…

COUNTRIESmedicine.medical_specialtyDyslipidaemiaAtherosclerosis; Cardiovascular; Dyslipidaemia; Low-density lipoprotein cholesterolCardiac & Cardiovascular SystemsIMPACTDYSLIPIDEMIACardiovascularGUIDELINESLipid-lowering therapySecondary CareSecondary careRisk FactorsCARDIOVASCULAR RISK-FACTORSMANAGEMENTMedicineHumansLow-density lipoprotein cholesterolCORONARY-HEART-DISEASE1102 Cardiorespiratory Medicine and HaematologyDyslipidemiasSecondary preventionLipid managementScience & Technologybusiness.industryDisease mortality1103 Clinical SciencesAtherosclerosisPREVENTIONLipidsPREVALENCEClinical PracticeEuropeCross-Sectional StudiesTreatment OutcomePeripheral Vascular DiseaseCardiovascular System & HematologyCardiovascular DiseasesFamily medicineEuropean atherosclerosis societyCardiovascular System & CardiologyObservational studyPolandHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessLife Sciences & BiomedicineAtherosclerosis
researchProduct